CMS intends for Medicare to cover Aduhelm, Biogen’s Alzheimer’s disease treatment, for patients taking part in clinical trials, the agency announced Jan. 11.
Read the full post on Becker's Hospital Review - Healthcare News
CMS unveils preliminary Aduhelm coverage decision
